293 Results

Additional data from SOPHIA study of margetuximab for HER2-positive metastatic breast cancer

 Added 5 days ago

MacroGenics, Inc.,has announced additional details of the results from the Phase III SOPHIA study of margetuximab in patients with HER2-positive...

Positive results from Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan to treat HER2-positive, unresectable breast cancer . Daiichi Sankyo + AstraZeneca

 Added 14 days ago

AstraZeneca and Daiichi Sankyo Company, Limited announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan...

Global HER2 testing survey raises questions about priorities for breast cancer resources

 Added 17 days ago

A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries.

FDA approves Kadcyla for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer

 Added 19 days ago

Genentech, announced that the FDA has approved Kadcyla (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early...

Breast Cancer: integrated care ahead of innovation

 Added 22 days ago

Report suggests that therapeutic innovations should go hand in hand with a multidisciplinary, fully integrated approach to patient care.

Breast cancer in young women: good outcomes with advised therapy

 Added 23 days ago

Report from ESMO Breast Cancer Congress 2019 Congress suggests a young age per se is not a reason to give more intensive treatment.

Sandoz licences EG 12014 (trastuzumab biosimilar) from EirGenix

 Added 23 days ago

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into an agreement to commercialize...

CHMP recommends approval of Talzenna in HER2- breast cancer

 Added 27 days ago

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending Talzenna (talazoparib)...

EMA approves Lynparza to treat patients with germline BRCA1/2-mutations (gBRCAm) with HER2-negative metastatic breast cancer

 Added 1 month ago

AstraZeneca and MSD Inc. have announced the European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of...

FDA expands indication of Ibrance to include HER2- breast cancer in males

 Added 1 month ago

The FDA is extending the indication of Ibrance (palbociclib), from Pfizer, capsules in combination with specific endocrine therapies for hormone...

Load more